Status:
COMPLETED
Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.
Lead Sponsor:
University Hospital, Angers
Conditions:
Myeloproliferative Disorder
Essential Thrombocythemia
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
Prospective study for the development of a non-invasive score for differentiating prefibrotic myelofibrosis from essential thrombocytosis and overt myelofibrosis.
Detailed Description
The diagnostic criteria for myeloproliferative neoplasia have recently been revised in the WHO 2016 classification, which now recognizes a new entity between essential thrombocythemia (TE) and overt m...
Eligibility Criteria
Inclusion
- Adult (18 years of age or older) with the diagnosis of essential thrombocytosis, prefibrotic myelofibrosis or overt myelofibrosis according to WHO 2016 criteria;
- Patient who has not received specific treatment for neoplasms;
- Patient who has signed the consent to participate in the study;
- Patient who has consented to be included in the "Malignant Haemopathies" collection at the University Hospital of Angers or Brest and for whom the samples necessary for the study are available in the biocollection.
Exclusion
- Patient with another hematologic neoplasm or progressive cancer at the time of diagnosis;
- Patient with a diagnosis of secondary myelofibrosis;
- Pregnant or breastfeeding woman;
- Person prived of liberty by judicial or administrative decision;
- Person subject to a legal protection measure;
Key Trial Info
Start Date :
July 30 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 30 2024
Estimated Enrollment :
133 Patients enrolled
Trial Details
Trial ID
NCT03869476
Start Date
July 30 2019
End Date
January 30 2024
Last Update
December 30 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Angers
Angers, France, 49000
2
CHRU de Brest - Hôpital Morvan
Brest, France, 29100